A trial fibrillation (AF) confers an increased risk of stroke and thromboembolism (TE), which is associated with high mortality and morbidity. The use of oral anticoagulation (OAC) therapy results in a 64% reduction in stroke and a 26% reduction in all-cause mortality compared with control/placebo. 1 Nonetheless, OAC confers a significant risk of serious bleeding, at least in historical trials, 1 although more contemporary data suggest no significant difference between OAC and aspirin. [2] [3] [4] 
and validated in an AF cohort. 10 In the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines, 11 bleeding risk assessment was not even considered. In 2010, the European Society of Cardiology guidelines recommended bleeding risk assessment, advocating the use of new Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/ alcohol concomitantly (HAS-BLED) score, which has the advantage of simplicity of calculation and where a score ≥3 necessitates caution and regular review. 12, 13 The 2011 Canadian Cardiovascular Society guidelines and their subsequent 2012 focused update also recommended bleeding risk assessment and use of HAS-BLED score. 14, 15 The HAS-BLED score was first proposed in 2010 after its derivation and validation in the EuroHeart survey. 13 Since then, this score has been validated in various independent real-world cohorts [16] [17] [18] and 1 trial cohort. 19 The HAS-BLED score has only been compared with the older schemes in 2 cohorts, one being the EuroHeart survey 13 and the other, a clinical trial cohort 19 ; no formal comparisons with the new Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) bleeding score 20 have been undertaken in an AF cohort representative of routine realworld clinical practice. The ATRIA score is a weighted score derived from a selected prospective cohort of anticoagulated AF patients, although various limitations have been highlighted. 21 The objective of the present analysis is to compare the HAS-BLED score against other older bleeding risk scores and the newer ATRIA score in a representative AF cohort. We tested the hypothesis that the HAS-BLED score would perform well as other older and relatively more complicated bleeding risk scores, as well as the new ATRIA score, in routine clinical practice.
Methods

Study Population
At the Centre Hospitalier Régional et Universitaire in Tours (France), all patients diagnosed with nonvalvular AF or atrial flutter by the Department of Cardiology between 2000 and 2010 were identified. The institution includes a total of 4 hospitals covering all medical and surgical specialties, the only public institution in an area of around 4000 km², serving ≈400 000 inhabitants. Patients with nonvalvular AF evaluated by the cardiology department were defined as those directly admitted to the inpatient cardiology service and those seen as a consultation in any service and subsequently proposed for admission in the cardiology department. The diagnosis of AF as confirmed by a cardiologist was needed to avoid the wrong diagnosis and to ensure that other diagnoses related to cardiac conditions were reliable because these were important factors used for calculating the several scores used.
Patients were followed from the first record of nonvalvular AF after January 1, 2000 (ie, index date), up to the latest data collection at the time of study (December 2010). Treatment at discharge was obtained by screening hospitalization reports, and information on comorbidities was obtained from the computerized coding system.
During follow-up, information on the study outcomes of major bleeding was recorded. Major bleeding was defined as bleeding with a reduction in the hemoglobin level of at least 20 g/L, or with transfusion of at least 1 unit of blood, or symptomatic bleeding in a critical area or organ (eg, intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), or bleeding that causes death. All information on bleeding was identified with the diagnosis coded in a subsequent hospitalization during follow-up; thus, we recorded all hospitalizations with a bleed as an additional criterion for major bleeding.
Bleeding Risk
For each patient, the HAS-BLED score was calculated as the sum of points obtained after adding 1 point for the presence of each individual factor. 22 Patients with an HAS-BLED score of 0 were deemed to have low bleeding risk, 1 to 2 as intermediate/moderate risk, and ≥3 as high bleeding risk.
We then tested the predictive value of several bleeding risk schema in this cohort: HEMORR 2 HAGES Risk Factors (score), 23 Beyth et al, 24 Kuijer et al, 25 Shireman et al, 22 and ATRIA 20 (online-only Data Supplement Table I ). For each risk stratification schema, we calculated the c-statistic as a measure of predictive accuracy. In the HEMORR 2 HAGES scheme, we considered systolic blood pressure >160 mm Hg as uncontrolled hypertension, a history of malignancy as similar to current malignancy, 20 units of alcohol consumption weekly as ethanol abuse, creatine clearance <50 mL/min as renal disease, and a low platelet count less than the lower limit of normal and hemoglobin content less than the lower limit of normal as anemia. Relevant genetic and laboratory data (required for calculation of some schemes), apart from serum creatinine and hematocrit, were not available. For HAS-BLED, labile international normalized ratio was defined as <60% time in the therapeutic range (international normalized ratio 2-3 inclusive), concomitant platelet inhibitor agents as aspirin or nonsteroidal antiinflammatory drugs, and elderly as age >65 years. 
Statistical Analysis
The study population was stratified into 3 categories according to HAS-BLED scores of bleeding risk, that is, high risk (HAS-BLED ≥3), moderate risk (HAS-BLED=1-2), and low risk (HAS-BLED=0) ( Figure) . Baseline characteristics were determined separately for the 3 bleeding risk strata, and differences were investigated using χ 2 test for categorical covariates and Kruskal-Wallis test for continuous covariates (Table 1 ). In each of the 3 bleeding risk categories, event rates of stroke/TE, bleeding, and death were calculated for patients with AF who were not receiving VKA.
The bleeding risk associated with the individual risk factors of the HAS-BLED score was estimated in Cox proportional hazard models. To increase the power of the analyses, the Cox regression models included patients with and without VKA; this approach was appropriate because no interaction was found between the effect of the individual risk factors and VKA treatment. Also, the recent analysis by Friberg et al 17 clearly shows that the major bleeding (and intracranial hemorrhage) rates on VKA were similar to aspirin-treated (ie, nonanticoagulated) patients, even when subdivided by HAS-BLED scores. Of note, the 2010 European guidelines state that the HAS-BLED score should be used "… to assess bleeding risk … (with) the initiation of antithrombotic therapy, whether with oral anticoagulation or aspirin." 12 Both univariable (including the individual risk factor and VKA treatment only) and multivariable (including all the HAS-BLED risk factors and VKA) Cox regression models were applied. Furthermore, the event rates of bleeding were calculated in patients with and without each of the HAS-BLED risk factors.
The hazard ratios associated with each of the 6 bleeding risk scores HAS-BLED, 13 HEMORR 2 HAGES, 23 Beyth et al, 24 Kuijer et al, 25 Shireman et al, 22 and ATRIA 20 were calculated by Cox regression (for the scores as continuous and categorical variables). For each risk scoring system, the c-statistic was calculated and compared with the HAS-BLED c-statistic using the DeLong test. The categorical version of the net reclassification improvement (NRI) was used to compare the reclassification by HAS-BLED versus other risk scoring systems.
A 2-sided P<0.05 was considered statistically significant for all analyses. All analyses were performed with SPSS statistical software version 18.0 (IBM).
Results
Our cohort consisted of 7156 patients with AF, of which 1254 (17.5%) were at high bleeding risk (HAS-BLED score ≥3), 4620 (64.6%) were at moderate risk (HAS-BLED 1-2), and 1282 (17.9%) were at low risk (HAS-BLED=0) (Figure) . Patient demography and clinical features are summarized in Table 1 . Paroxysmal AF was more common among low-risk subjects, whereas various clinical risk factors (eg, hypertension), prior bleeding, and an excessive risk of falls were, unsurprisingly, more common among high-risk subjects. VKA use was highest in moderate-risk patients (59.8%) but only slightly more than that in high-risk (50.1%) and lowrisk (46.4%) patients. High-risk patients also had high stroke risk, as reflected by their CHADS 2 Event rates for stroke, TE, death, and bleeding are shown in Table 2 . Those at high bleeding risk (HAS-BLED ≥3) were also at highest risk of the composite end point of stroke/TE or stroke/TE/death, as well as bleeding and all-cause mortality.
On multivariable analysis, independent predictors of bleeding were age ≥75 (hazard ratio, AF indicates atrial fibrillation; ICD, implantable cardiac defibrillator; INR, international normalized ratio; CHADS 2 , 1 point each for congestive heart failure, hypertension, age ≥75, and diabetes mellitus, and 2 points for previous stroke or thromboembolism; CHA 2 DS 2 -VASc, 1 point for congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65 to 74, and female sex, and 2 points for previous stroke or thromboembolism and age ≥75; HAS-BLED, hypertension, abnormal renal and liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly (> 65 y); NSAIDs, nonsteroidal anti-inflammatory drugs; ACE, angiotensin-converting enzyme.
rates in patients with AF and not receiving VKA are shown in Table 4 in relation to the presence or absence of risk factors. All risk scoring systems tested (whether as categorical or continuous score, as relevant) resulted in a significant hazard ratio for increased bleeding on univariable analysis ( Table 5 ).
The predictive value for bleeding events, evidenced by c-statistics for the various scores, is presented in Table 6 . All scores had only modest predictive ability for bleeding whether on VKA or not (c-statistic ≈0.60), with the HAS-BLED score having a c-statistic (and 95% CIs) better than chance, whether tested as a continuous or categorical (ie, low, moderate, and high risk) score, in both VKA-treated and non-VKA-treated patients.
For patients on VKA, the HEMORR 2 HAGES, Kuijer, and Shireman scores were not significantly better than chance (95% CIs for c-statistics include 0.50) when tested as a categorical variable. For patients on non-VKA, the HEMORR 2 HAGES, Kuijer, Shireman, and ATRIA scores were not significantly better than chance (95% CIs for c-statistics include 0.50) when tested as a categorical variable (ie, low, moderate, and high risk).
When the HAS-BLED score was compared with other bleeding risk scores, the NRI was significantly improved against all other scores tested ( Table 7 ). The HAS-BLED scoring system led to a (significant) positive NRI compared with the other 5 commonly used bleeding risk scoring systems (ranging from 6.6% with ATRIA to 11.7% with Shireman).
Discussion
In this study, we have shown how the HAS-BLED score performs in relation to predicting bleeding events compared with older bleeding scores (HEMORR 2 HAGES, 23 Beyth et al, 24 Kuijer et al, 25 Shireman et al 22 ) and the new ATRIA score. 20 Although the predictive ability using the c-statistic was modest (≈0.6) for most of the scores, the NRI showed improved reclassification using HAS-BLED compared with all other tested bleeding risk scores, including ATRIA. Of the tested scores, only the HAS-BLED score had a c-statistic (and 95% CIs) better than chance, whether tested as a continuous or categorical (ie, low, moderate, and high risk) score, in both VKA-treated and non-VKA-treated patients Unsurprisingly, patients with paroxysmal AF were more common among subjects at low risk of bleeding, but while VKA use was highest in moderate-risk patients this was only slightly higher than those patients who were at high or low risk using the HAS-BLED score. Given that some of the decisions about VKA use were made before the availability of the HAS-BLED score 13 and publication of the 2010 European Society of Cardiology guidelines, 12 this would suggest that bleeding risk estimation by clinicians was poor, and OAC prescribing practice did not reflect bleeding risk per se. INR indicates international normalized ratio; VKA, vitamin K antagonist; NSAID, nonsteroidal anti-inflammatory drug.
*As this table refers to patients not receiving VKA treatment, some patients may have had a history of labile INR (while previously receiving VKA) and were not treated with VKA at discharge of their hospitalization in the cardiology department.
†The D was quoted when patients, in addition to their anticoagulant treatment for AF, were also treated with any other concomitant medication with a risk of bleeding (aspirin, NSAID, etc). October 2012
High-risk patients also had high stroke risk, as reflected by CHADS 2 or CHA 2 DS 2 -VASc scores. Indeed, this translated to the observation that those at high bleeding risk (HAS-BLED ≥3) were also at highest risk of stroke/TE or stroke/TE/death, as well as bleeding and all-cause mortality. Gallego et al 18 recently reported that the HAS-BLED score was a good predictor of major bleeding (c-statistic ≈0.7), being as good as a multivariable analysis; however, the HAS-BLED score was only modestly predictive of cardiovascular events or death and less good compared with multivariable analysis for these outcomes because it is a score designed to predict bleeding rather than cardiovascular events or death. Other independent analyses comparing the HAS-BLED score have also found its predictive value to be as good as, and possibly better, than the older scores, 16, 17 with the highest c-statistic (≈0.8) in anticoagulated subjects seen in the nationwide cohort study by Olesen et al. 16 However, it would be inappropriate to directly compare c-statistics in one study with another, given the differences in study population, follow-up, and so on. In this cohort, independent predictors of bleeding were age (whether categorized as age ≥75 years or age ≥65 years), alcohol excess, and anemia (reflective perhaps of bleeding tendency or predisposition), which are represented within the HAS-BLED score. Other elements of HAS-BLED, such as concomitant drugs and hypertension, were not statistically significant, although point estimates were suggestive of increased risk. Interestingly, heart failure, excessive risk of falls, and smoking were also suggestive of risk. In an analysis of bleeding risk factors from the Stroke Prevention using an Oral Direct Thrombin Inhibitor in Atrial Fibrillation trials, heart failure (as reflected by left ventricular systolic dysfunction) also emerged as an independent risk factor for bleeding. 19 The impact of heart failure on bleeding risk scoring systems merits further consideration in further analyses.
All risk scoring systems tested (whether as categorical or continuous score, as relevant) resulted in a significant hazard for increased bleeding on univariable analyses. However, the predictive value for bleeding events, as evident by c-statistics, only showed modest predictive ability for bleeding whether on VKA or not (c-statistic ≈0.6). Major limitations of the c-statistic for assessing the predictive value have been highlighted, and other methods, such as the NRI, have been proposed. 26, 27 In the present study, when the HAS-BLED score was compared with other bleeding risk scores, the NRI was significantly improved (by 6.6%-11.7%) against all other scores tested, including the new ATRIA score.
Study Limitations
The limitations of this registry have been previously reported, with the inherent limitations of diagnostic coding and case ascertainment, particularly if an enrolled patient moved away from the area or had an outcome event in another area. Nevertheless, most patients with a major or fatal bleed, as far as it is identified, are likely to be seen in one department of our institution and not in any other institution. Our definition of major bleeding is also slightly different from the International Society of Thrombosis and Hemostasis definition, because we included the criterion of transfusion of at least 1 unit of blood, instead of 2 units used within the International Society of Thrombosis and Hemostasis definition; although this was partly because blood transfusion was coded in our hospital records (rather than units of blood), our criteria would be more inclusive of bleeding complications, where evident.
Despite statistical adjustment for several risk factors, the nonrandomized cohort design does not exclude the possibility of residual confounding factors. The present study was to focus on testing the hypothesis that the HAS-BLED score would perform well as other older and relatively more complicated bleeding risk scores in clinical practice (in this case, hospital practice). There may be clinical differences between inpatients and outpatients, which would affect the generalizability of our findings to the outpatient setting or to AF diagnosed outside the cardiology department. Inpatients usually have an acute illness or decompensation of a chronic illness that leads to hospitalization, which is different from outpatients. For example, heart failure, which impacts bleeding risk in our study, may be underrepresented in an outpatient or primary care cohort. Patients with AF seen in the cardiology department were 53% of all AF patients seen in the institution and 82% of all AF patients seen in several medical departments of our institution. Our study population is, therefore, representative of inpatients presenting to hospital with AF but may not wholly reflect the AF population in the outpatient or primary care setting.
Conclusions
In relation to predicting bleeding events, the HAS-BLED score outperforms older bleeding scores and the new ATRIA score. Indeed, the NRI showed improved reclassification using HAS-BLED compared with all other tested bleeding risk scores. Of note, OAC prescribing patterns would suggest that bleeding risk estimation by clinicians was poor and OAC prescribing practice did not reflect bleeding risk per se. Therefore, formal assessment of bleeding risk with (preferably) the HAS-BLED score would enhance clinical decision making, as recommended in current guidelines. 12, 14, 15 HAS-BLED score indicates hypertension, abnormal renal and liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly, drugs/alcohol concomitantly score; NRI: net reclassification improvement.
